Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis

Liwei Zhuang,Junnan Li,Yu Zhang,Shibo Ji,Yue Li,Yingying Zhao,Ben Li,Wei Li,Min Quan,Ying Duan,Hong Zhao,Danying Cheng,Xiaomei Wang,Weini Ou,Huichun Xing

Annals of Hepatology（2021）

引用 0|浏览8

暂无评分

摘要

Patients with hepatitis C virus (HCV) genotype 3 (GT3) infection are resistant to direct-acting antiviral (DAA) treatments. This study aimed to analyze the effectiveness of sofosbuvir (SOF)+daclatasvir (DCV) ± ribavirin (RBV); SOF+velpatasvir (VEL)±RBV; SOF+VEL+voxilaprevir (VOX); and glecaprevir (GLE)+pibrentasvir (PIB) in the treatment of HCV GT3-infected patients in real-world studies.

查看译文

关键词

DAA,DCV,EMA,FDA,GLE,HCV,PIB,RBV,RASs,SOF,SVR,VEL,VOX,WHO

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要